KMDA
Price
$7.44
Change
+$0.23 (+3.19%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
430.52M
69 days until earnings call
Intraday BUY SELL Signals
TEVA
Price
$34.55
Change
+$0.97 (+2.89%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
40.73B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KMDA vs TEVA

Header iconKMDA vs TEVA Comparison
Open Charts KMDA vs TEVABanner chart's image
KMDA vs TEVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KMDA vs. TEVA commentary
Jun 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and TEVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 12, 2026
Stock price -- (KMDA: $7.44 vs. TEVA: $33.58)
Brand notoriety: KMDA: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 55% vs. TEVA: 62%
Market capitalization -- KMDA: $430.52M vs. TEVA: $40.73B
KMDA [@Pharmaceuticals: Generic] is valued at $430.52M. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $40.73B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 1 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 1 green, 4 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 3 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 5 bearish.
  • TEVA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than TEVA.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а +0.81% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +2.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.97%. For the same industry, the average monthly price growth was +22.47%, and the average quarterly price growth was +8.19%.

Reported Earning Dates

KMDA is expected to report earnings on Aug 19, 2026.

TEVA is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.97% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($40.7B) has a higher market cap than KMDA($431M). TEVA has higher P/E ratio than KMDA: TEVA (25.06) vs KMDA (21.26). KMDA YTD gains are higher at: 8.576 vs. TEVA (7.594). TEVA has higher annual earnings (EBITDA): 3.27B vs. KMDA (38.3M). TEVA has more cash in the bank: 3.74B vs. KMDA (23.1M). KMDA has less debt than TEVA: KMDA (11.5M) vs TEVA (16.9B). TEVA has higher revenues than KMDA: TEVA (17.3B) vs KMDA (182M).
KMDATEVAKMDA / TEVA
Capitalization431M40.7B1%
EBITDA38.3M3.27B1%
Gain YTD8.5767.594113%
P/E Ratio21.2625.0685%
Revenue182M17.3B1%
Total Cash23.1M3.74B1%
Total Debt11.5M16.9B0%
FUNDAMENTALS RATINGS
KMDA vs TEVA: Fundamental Ratings
KMDA
TEVA
OUTLOOK RATING
1..100
6564
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
6218
SMR RATING
1..100
7943
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
7087
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for TEVA (68) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew somewhat faster than TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (18) in the Pharmaceuticals Generic industry is somewhat better than the same rating for KMDA (62) in the Biotechnology industry. This means that TEVA’s stock grew somewhat faster than KMDA’s over the last 12 months.

TEVA's SMR Rating (43) in the Pharmaceuticals Generic industry is somewhat better than the same rating for KMDA (79) in the Biotechnology industry. This means that TEVA’s stock grew somewhat faster than KMDA’s over the last 12 months.

TEVA's Price Growth Rating (42) in the Pharmaceuticals Generic industry is in the same range as KMDA (61) in the Biotechnology industry. This means that TEVA’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's P/E Growth Rating (70) in the Biotechnology industry is in the same range as TEVA (87) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to TEVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDATEVA
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 16 days ago
66%
Bullish Trend 23 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
61%
Bearish Trend 4 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signal:
Gain/Loss:
TEVA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGLDX30.400.76
+2.56%
American Funds Global Insight R-3
CSVZX45.31N/A
N/A
Columbia Select Large Cap Value Inst
JUSMX21.27N/A
N/A
JPMorgan US Small Company R6
TQMVX20.78N/A
N/A
T. Rowe Price Integrated US LCV Eq
OSTGX19.92N/A
N/A
Osterweis Opportunity Fund

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-2.53%
AMRX - TEVA
46%
Loosely correlated
+4.29%
NBIX - TEVA
42%
Loosely correlated
-2.71%
VTRS - TEVA
34%
Loosely correlated
-2.65%
COLL - TEVA
33%
Poorly correlated
+1.16%
KMDA - TEVA
30%
Poorly correlated
-0.41%
More